Trait: prostate cancer

Trait Information
Identifier MONDO_0008315
Description A primary or metastatic malignant tumor involving the prostate gland. The vast majority are carcinom... as. [NCIT: C7378]Show more
Trait category
Cancer
Synonyms 21 synonyms
  • NGP - new growth of prostate
  • cancer of prostate gland
  • hereditary prostate cancer
  • malignant neoplasm of prostate
  • malignant neoplasm of prostate gland
  • malignant neoplasm of the prostate
  • malignant prostate gland neoplasm
  • malignant prostate neoplasm
  • malignant prostate tumor
  • malignant prostate tumour
  • malignant tumor of prostate
  • malignant tumor of the prostate
  • malignant tumour of prostate
  • malignant tumour of the prostate
  • prostate cancer, familial
  • prostate gland cancer
  • prostate neoplasm
  • prostatic cancer
  • prostatic neoplasm
  • tumor of the prostate
  • tumour of the prostate
Mapped terms 7 mapped terms
  • DOID:10283
  • ICD9:185
  • MEDGEN:138169
  • MESH:D011471
  • NCIT:C7378
  • SCTID:399068003
  • UMLS:C0376358
Child trait(s) 2 child traits

Associated Polygenic Score(s)

Filter PGS by Participant Ancestry
Individuals included in:
G - Source of Variant Associations (GWAS)
D - Score Development/Training
E - PGS Evaluation
List of ancestries includes:
Display options:
Ancestry legend
Multi-ancestry (including European)
Multi-ancestry (excluding European)
African
East Asian
South Asian
Additional Asian Ancestries
European
Greater Middle Eastern
Hispanic or Latin American
Additional Diverse Ancestries
Not Reported
Note: This table shows all PGS for "prostate cancer" and any child terms of this trait in the EFO hierarchy by default.
JSONXMLCSVTXTMS-Excel
Loading, please wait
Polygenic Score ID & Name
PGS Publication ID (PGP)
Reported Trait
Mapped Trait(s) (Ontology)
Number of Variants
Ancestry distribution
GWAS
Dev
Eval
Scoring File (FTP Link)
PGS000030
(PrCa)
PGP000019 |
Schumacher FR et al. Nat Genet (2018)
Prostate cancerprostate carcinoma147
G
-
E
 https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000030/ScoringFiles/PGS000030.txt.gz
PGS000044
(PrCa66)
PGP000031 |
Pashayan N et al. Br J Cancer (2015)
Prostate cancerprostate carcinoma66
G
-
E
 https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000044/ScoringFiles/PGS000044.txt.gz
PGS000049
(PRS103_PrCa)
PGP000034 |
Lecarpentier J et al. J Clin Oncol (2017)
Prostate cancerprostate carcinoma103
G
-
E
 https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000049/ScoringFiles/PGS000049.txt.gz
PGS000067
(PCa_PHS)
PGP000047 |
Seibert TM et al. BMJ (2018)
Prostate cancerprostate carcinoma54
-
D
E
 https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000067/ScoringFiles/PGS000067.txt.gz
PGS000084
(CC_Prostate)
PGP000050 |
Graff RE et al. Nat Commun (2021)
Prostate cancerprostate carcinoma161
G
-
E
 https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000084/ScoringFiles/PGS000084.txt.gz
PGS000160
(cGRS_Prostate)
PGP000075 |
Shi Z et al. Cancer Med (2019)
Prostate cancerprostate carcinoma79
G
-
E
 https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000160/ScoringFiles/PGS000160.txt.gz
PGS000333
(PRS_PC)
PGP000100 |
Mars N et al. Nat Med (2020)
Prostate cancerprostate carcinoma6,606,785
G
D
E
 https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000333/ScoringFiles/PGS000333.txt.gz
PGS000348
(PRS_PrCa)
PGP000113 |
Black MH et al. Prostate (2020)
Prostate cancerprostate carcinoma72
G
-
E
 https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000348/ScoringFiles/PGS000348.txt.gz - Check Terms/Licenses
PGS000565
(PRSWEB_PHECODE185_20001-1044_P_5e-08_MGI_20200608)
PGP000118 |
Fritsche LG et al. Am J Hum Genet (2020)
Prostate cancerprostate carcinoma21
G
D
E
 https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000565/ScoringFiles/PGS000565.txt.gz
PGS000566
(PRSWEB_PHECODE185_20001-1044_PRS-CS_MGI_20200608)
PGP000118 |
Fritsche LG et al. Am J Hum Genet (2020)
Prostate cancerprostate carcinoma1,111,494
G
D
E
 https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000566/ScoringFiles/PGS000566.txt.gz
PGS000567
(PRSWEB_PHECODE185_20001-1044_PT_MGI_20200608)
PGP000118 |
Fritsche LG et al. Am J Hum Genet (2020)
Prostate cancerprostate carcinoma78
G
D
E
 https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000567/ScoringFiles/PGS000567.txt.gz
PGS000568
(PRSWEB_PHECODE185_20001-1044_LASSOSUM_MGI_20200608)
PGP000118 |
Fritsche LG et al. Am J Hum Genet (2020)
Prostate cancerprostate carcinoma1,401
G
D
E
 https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000568/ScoringFiles/PGS000568.txt.gz
PGS000569
(PRSWEB_PHECODE185_C3-PROSTATE_P_5e-08_MGI_20200608)
PGP000118 |
Fritsche LG et al. Am J Hum Genet (2020)
Prostate cancerprostate carcinoma49
G
D
E
 https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000569/ScoringFiles/PGS000569.txt.gz
PGS000570
(PRSWEB_PHECODE185_C3-PROSTATE_PRS-CS_MGI_20200608)
PGP000118 |
Fritsche LG et al. Am J Hum Genet (2020)
Prostate cancerprostate carcinoma1,111,493
G
D
E
 https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000570/ScoringFiles/PGS000570.txt.gz
PGS000571
(PRSWEB_PHECODE185_C3-PROSTATE_PT_MGI_20200608)
PGP000118 |
Fritsche LG et al. Am J Hum Genet (2020)
Prostate cancerprostate carcinoma100
G
D
E
 https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000571/ScoringFiles/PGS000571.txt.gz
PGS000572
(PRSWEB_PHECODE185_C3-PROSTATE_LASSOSUM_MGI_20200608)
PGP000118 |
Fritsche LG et al. Am J Hum Genet (2020)
Prostate cancerprostate carcinoma1,809
G
D
E
 https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000572/ScoringFiles/PGS000572.txt.gz
PGS000573
(PRSWEB_PHECODE185_C61_P_5e-08_MGI_20200608)
PGP000118 |
Fritsche LG et al. Am J Hum Genet (2020)
Prostate cancerprostate carcinoma31
G
D
E
 https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000573/ScoringFiles/PGS000573.txt.gz
PGS000574
(PRSWEB_PHECODE185_C61_PRS-CS_MGI_20200608)
PGP000118 |
Fritsche LG et al. Am J Hum Genet (2020)
Prostate cancerprostate carcinoma1,111,493
G
D
E
 https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000574/ScoringFiles/PGS000574.txt.gz
PGS000575
(PRSWEB_PHECODE185_C61_PT_MGI_20200608)
PGP000118 |
Fritsche LG et al. Am J Hum Genet (2020)
Prostate cancerprostate carcinoma47
G
D
E
 https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000575/ScoringFiles/PGS000575.txt.gz
PGS000576
(PRSWEB_PHECODE185_C61_LASSOSUM_MGI_20200608)
PGP000118 |
Fritsche LG et al. Am J Hum Genet (2020)
Prostate cancerprostate carcinoma905
G
D
E
 https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000576/ScoringFiles/PGS000576.txt.gz
PGS000577
(PRSWEB_PHECODE185_GWAS-Catalog-r2019-05-03-X185_P_5e-08_MGI_20200608)
PGP000118 |
Fritsche LG et al. Am J Hum Genet (2020)
Prostate cancerprostate carcinoma117
G
D
E
 https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000577/ScoringFiles/PGS000577.txt.gz
PGS000578
(PRSWEB_PHECODE185_GWAS-Catalog-r2019-05-03-X185_P_5e-08_UKB_20200608)
PGP000118 |
Fritsche LG et al. Am J Hum Genet (2020)
Prostate cancerprostate carcinoma117
G
D
E
 https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000578/ScoringFiles/PGS000578.txt.gz
PGS000579
(PRSWEB_PHECODE185_GWAS-Catalog-r2019-05-03-X185_PT_MGI_20200608)
PGP000118 |
Fritsche LG et al. Am J Hum Genet (2020)
Prostate cancerprostate carcinoma122
G
D
E
 https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000579/ScoringFiles/PGS000579.txt.gz
PGS000580
(PRSWEB_PHECODE185_GWAS-Catalog-r2019-05-03-X185_PT_UKB_20200608)
PGP000118 |
Fritsche LG et al. Am J Hum Genet (2020)
Prostate cancerprostate carcinoma118
G
D
E
 https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000580/ScoringFiles/PGS000580.txt.gz
PGS000581
(PRSWEB_PHECODE185_Pca-PRACTICAL_P_5e-08_MGI_20200608)
PGP000118 |
Fritsche LG et al. Am J Hum Genet (2020)
Prostate cancerprostate carcinoma377
G
D
E
 https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000581/ScoringFiles/PGS000581.txt.gz
PGS000582
(PRSWEB_PHECODE185_Pca-PRACTICAL_P_5e-08_UKB_20200608)
PGP000118 |
Fritsche LG et al. Am J Hum Genet (2020)
Prostate cancerprostate carcinoma377
G
D
E
 https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000582/ScoringFiles/PGS000582.txt.gz
PGS000583
(PRSWEB_PHECODE185_Pca-PRACTICAL_PRS-CS_MGI_20200608)
PGP000118 |
Fritsche LG et al. Am J Hum Genet (2020)
Prostate cancerprostate carcinoma1,119,311
G
D
E
 https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000583/ScoringFiles/PGS000583.txt.gz
PGS000584
(PRSWEB_PHECODE185_Pca-PRACTICAL_PRS-CS_UKB_20200608)
PGP000118 |
Fritsche LG et al. Am J Hum Genet (2020)
Prostate cancerprostate carcinoma1,120,596
G
D
E
 https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000584/ScoringFiles/PGS000584.txt.gz
PGS000585
(PRSWEB_PHECODE185_Pca-PRACTICAL_PT_MGI_20200608)
PGP000118 |
Fritsche LG et al. Am J Hum Genet (2020)
Prostate cancerprostate carcinoma1,301
G
D
E
 https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000585/ScoringFiles/PGS000585.txt.gz
PGS000586
(PRSWEB_PHECODE185_Pca-PRACTICAL_PT_UKB_20200608)
PGP000118 |
Fritsche LG et al. Am J Hum Genet (2020)
Prostate cancerprostate carcinoma1,023
G
D
E
 https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000586/ScoringFiles/PGS000586.txt.gz
PGS000587
(PRSWEB_PHECODE185_Pca-PRACTICAL_LASSOSUM_MGI_20200608)
PGP000118 |
Fritsche LG et al. Am J Hum Genet (2020)
Prostate cancerprostate carcinoma26,418
G
D
E
 https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000587/ScoringFiles/PGS000587.txt.gz
PGS000588
(PRSWEB_PHECODE185_Pca-PRACTICAL_LASSOSUM_UKB_20200608)
PGP000118 |
Fritsche LG et al. Am J Hum Genet (2020)
Prostate cancerprostate carcinoma178,259
G
D
E
 https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000588/ScoringFiles/PGS000588.txt.gz
PGS000589
(PRSWEB_PHECODE185_UKBB-SAIGE-HRC-X185_P_5e-08_MGI_20200608)
PGP000118 |
Fritsche LG et al. Am J Hum Genet (2020)
Prostate cancerprostate carcinoma42
G
D
E
 https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000589/ScoringFiles/PGS000589.txt.gz
PGS000590
(PRSWEB_PHECODE185_UKBB-SAIGE-HRC-X185_PRS-CS_MGI_20200608)
PGP000118 |
Fritsche LG et al. Am J Hum Genet (2020)
Prostate cancerprostate carcinoma1,119,236
G
D
E
 https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000590/ScoringFiles/PGS000590.txt.gz
PGS000591
(PRSWEB_PHECODE185_UKBB-SAIGE-HRC-X185_PT_MGI_20200608)
PGP000118 |
Fritsche LG et al. Am J Hum Genet (2020)
Prostate cancerprostate carcinoma80
G
D
E
 https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000591/ScoringFiles/PGS000591.txt.gz
PGS000592
(PRSWEB_PHECODE185_UKBB-SAIGE-HRC-X185_LASSOSUM_MGI_20200608)
PGP000118 |
Fritsche LG et al. Am J Hum Genet (2020)
Prostate cancerprostate carcinoma1,334
G
D
E
 https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000592/ScoringFiles/PGS000592.txt.gz
PGS000662
(GRS.PCa.269)
PGP000122 |
Conti DV et al. Nat Genet (2021)
Prostate cancerprostate carcinoma269
G
-
E
 https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000662/ScoringFiles/PGS000662.txt.gz
PGS000714
(PRS55_PC)
PGP000130 |
Sipeky C et al. Sci Rep (2020)
Prostate cancerprostate carcinoma55
G
-
E
 https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000714/ScoringFiles/PGS000714.txt.gz
PGS000719
(PRS_Prostate)
PGP000135 |
Jia G et al. JNCI Cancer Spectr (2020)
Prostate cancerprostate carcinoma134
G
-
E
 https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000719/ScoringFiles/PGS000719.txt.gz
PGS000733
(PHS46+African)
PGP000139 |
Karunamuni RA et al. Int J Cancer (2020)
Prostate cancerprostate carcinoma49
G
D
E
 https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000733/ScoringFiles/PGS000733.txt.gz
PGS000741
(PCa_PHS2)
PGP000149 |
Huynh-Le MP et al. Nat Commun (2021)
Prostate cancerprostate carcinoma46
-
D
E
 https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000741/ScoringFiles/PGS000741.txt.gz
PGS000742
(PHS166)
PGP000150 |
Karunamuni RA et al. Prostate Cancer Prostatic Dis (2021)
Prostate cancerprostate carcinoma166
G
D
E
 https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000742/ScoringFiles/PGS000742.txt.gz
PGS000751
(PRS_PrCa_EuropeanWeighted)
PGP000156 |
Du Z et al. Int J Cancer (2019)
Prostate cancerprostate carcinoma178
G
-
E
 https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000751/ScoringFiles/PGS000751.txt.gz
PGS000795
(CC_Prostate_IV)
PGP000186 |
Kachuri L et al. Nat Commun (2020)
Prostate cancerprostate carcinoma161
G
-
E
 https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000795/ScoringFiles/PGS000795.txt.gz
PGS000878
(PRS4_PC)
PGP000224 |
Oh JJ et al. Front Oncol (2020)
Prostate cancerprostate carcinoma4
G
-
E
 https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000878/ScoringFiles/PGS000878.txt.gz
PGS000881
(GRS72_PCa)
PGP000227 |
Xu J et al. Prostate (2021)
Prostate cancerprostate carcinoma72
G
-
E
 https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000881/ScoringFiles/PGS000881.txt.gz
PGS001291
(GBE_cancer1044)
PGP000244 |
Tanigawa Y et al. PLoS Genet (2022)
Prostate cancerprostate carcinoma948
-
D
E
 https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS001291/ScoringFiles/PGS001291.txt.gz
PGS001805
(portability-PLR_185)
PGP000263 |
Privé F et al. Am J Hum Genet (2022)
Prostate cancerprostate carcinoma2,579
-
D
E
 https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS001805/ScoringFiles/PGS001805.txt.gz
PGS002016
(portability-ldpred2_185)
PGP000263 |
Privé F et al. Am J Hum Genet (2022)
Prostate cancerprostate carcinoma450,963
-
D
E
 https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS002016/ScoringFiles/PGS002016.txt.gz
PGS002240
(prscs_prostatecancer)
PGP000271 |
Mars N et al. Cell Genom (2022)
Prostate cancerprostate carcinoma1,092,093
G
D
E
 https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS002240/ScoringFiles/PGS002240.txt.gz
Showing 1 to 50 of 89 rows
152550100All
rows per page

Performance Metrics

Disclaimer: The performance metrics are displayed as reported by the source studies. It is important to note that metrics are not necessarily comparable with each other. For example, metrics depend on the sample characteristics (described by the PGS Catalog Sample Set [PSS] ID), phenotyping, and statistical modelling. Please refer to the source publication for additional guidance on performance.

JSONXMLCSVTXTMS-Excel
Loading, please wait
PGS Performance
Metric ID (PPM)
Evaluated Score
PGS Sample Set ID
(PSS)
Performance Source
Trait
PGS Effect Sizes
(per SD change)
Classification Metrics
Other Metrics
Covariates Included in the Model
PGS Performance:
Other Relevant Information
PPM000061PGS000030
(PrCa)
PSS000041|
European Ancestry|
74,849 individuals
PGP000019 |
Schumacher FR et al. Nat Genet (2018)
Reported Trait: Prostate cancerOR: 1.86 [1.83, 1.89]——Top 7 Genetic PCs, countrySamples were also part of the variant association
PPM000104PGS000044
(PrCa66)
PSS000068|
European Ancestry|
17,012 individuals
PGP000031 |
Pashayan N et al. Br J Cancer (2015)
Reported Trait: Elevated serum prostate-specific antigen (PSA) levels——OR (per 1-point increase in PRS): 1.23 [1.1, 1.37]cancer stage, Gleason score—
PPM000105PGS000044
(PrCa66)
PSS000069|
European Ancestry|
4,967 individuals
PGP000032 |
Pashayan N et al. Genet Med (2015)
|Ext.		Reported Trait: aggressive prostate cancer (Gleason score ⩾7)——OR (above vs. below 50th percentile of PRS): 1.56 [1.15, 2.1]——
PPM000123PGS000049
(PRS103_PrCa)
PSS000075|
European Ancestry|
1,525 individuals
PGP000034 |
Lecarpentier J et al. J Clin Oncol (2017)
Reported Trait: Prostate cancer in male carriers of BRCA1/2 mutationsOR: 1.56 [1.35, 1.81]AUROC: 0.62 [0.58, 0.66]—3 PCs of ancestry, age at breast or prostate cancer for patient-cases and age at interview for contr... ols, mutation status of BRCA1 or BRCA2Show more—
PPM000124PGS000049
(PRS103_PrCa)
PSS000077|
European Ancestry|
1,366 individuals
PGP000034 |
Lecarpentier J et al. J Clin Oncol (2017)
Reported Trait: Low prostate cancer aggressiveness (Gleason score < 7)OR: 1.44 [1.1, 1.87]——3 PCs of ancestry, age at breast or prostate cancer for patient-cases and age at interview for contr... ols, mutation status of BRCA1 or BRCA2Show more—
PPM000125PGS000049
(PRS103_PrCa)
PSS000076|
European Ancestry|
3,325 individuals
PGP000034 |
Lecarpentier J et al. J Clin Oncol (2017)
Reported Trait: High prostate cancer aggressiveness (Gleason score ≥ 7)OR: 1.67 [1.37, 2.04]——3 PCs of ancestry, age at breast or prostate cancer for patient-cases and age at interview for contr... ols, mutation status of BRCA1 or BRCA2Show more—
PPM000182PGS000067
(PCa_PHS)
PSS000105|
European Ancestry|
5,456 individuals
PGP000047 |
Seibert TM et al. BMJ (2018)
Reported Trait: aggressive prostate cancer——HR (Hazard ratio; top 2% vs. average risk): 2.9 [2.4, 3.4]——
PPM000183PGS000067
(PCa_PHS)
PSS000105|
European Ancestry|
5,456 individuals
PGP000047 |
Seibert TM et al. BMJ (2018)
Reported Trait: aggressive prostate cancer (age at onset)——z-test (p-value) <: 1.00e-16——
PPM000184PGS000067
(PCa_PHS)
PSS000106|
European Ancestry|
6,411 individuals
PGP000047 |
Seibert TM et al. BMJ (2018)
Reported Trait: any prostate cancer——HR (Hazard ratio; top 2% vs. average risk): 2.5 [2.2, 2.8]——
PPM000185PGS000067
(PCa_PHS)
PSS000106|
European Ancestry|
6,411 individuals
PGP000047 |
Seibert TM et al. BMJ (2018)
Reported Trait: any prostate cancer (age at onset)——z-test (p-value) <: 1.00e-16——
PPM000186PGS000067
(PCa_PHS)
PSS000107|
European Ancestry|
5,048 individuals
PGP000047 |
Seibert TM et al. BMJ (2018)
Reported Trait: very aggressive prostate cancer——HR (Hazard ratio; top 2% vs. average risk): 3.0 [2.2, 4.0]——
PPM000187PGS000067
(PCa_PHS)
PSS000107|
European Ancestry|
5,048 individuals
PGP000047 |
Seibert TM et al. BMJ (2018)
Reported Trait: very aggressive prostate cancer (age at onset)——z-test (p-value) <: 1.00e-16——
PPM000204PGS000084
(CC_Prostate)
PSS000123|
European Ancestry|
201,516 individuals
PGP000050 |
Graff RE et al. Nat Commun (2021)
Reported Trait: Prostate cancerOR: 1.44 [1.41, 1.47]——Genotyping reagent kit (GERA cohort only), genotyping array (UK Biobank only), age, 10 PCs.Results from meta-analysis of GERA and UKB. Sample overlap: the GERA dataset contributed to the effe... ct estimates for 4 of the 161 variants in the prostate cancer PRS.Show more
PPM000390PGS000067
(PCa_PHS)
PSS000220|
Multi-ancestry (including European)|
56,994 individuals
PGP000058 |
Huynh-Le MP et al. Nat Commun (2021)
|Ext.		Reported Trait: Age of aggressive prostate cancer onset——Hazard Ratio (HR; top 20% vs. rest): 5.9 [5.5, 6.3]—Association between PHS and age-at-onset p-value < 10e-16. Only SNPs directly genotyped on the On... coArray genotyping array were considered. 46 of the score's 54 SNPs were used: 24 directly genotyped, and 22 with acceptable proxies (r2>0.94).Show more
PPM000391PGS000067
(PCa_PHS)
PSS000223|
European Ancestry|
50,656 individuals
PGP000058 |
Huynh-Le MP et al. Nat Commun (2021)
|Ext.		Reported Trait: Age of aggressive prostate cancer onset——Hazard Ratio (HR; top 20% vs. rest): 5.6 [5.2, 6.0]—Association between PHS and age-at-onset p-value < 10e-16. Only SNPs directly genotyped on the On... coArray genotyping array were considered. 46 of the score's 54 SNPs were used: 24 directly genotyped, and 22 with acceptable proxies (r2>0.94).Show more
Showing 1 to 15 of 348 rows
152550100200All
rows per page

Evaluated Samples

JSONXMLCSVTXTMS-Excel
Loading, please wait
PGS Sample Set ID
(PSS)
Phenotype Definitions and Methods
Participant Follow-up Time
Sample Numbers
Age of Study Participants
Sample Ancestry
Additional Ancestry Description
Cohort(s)
Additional Sample/Cohort Information
PSS000041For each cohort core data on disease status, age at diagnosis (age at observation or questionnaire f... or controls), family history of PrCa, and clinical factors for cases (for example, PSA at diagnosis and Gleason score) was extractedShow more—
[
  • 46,939 cases
  • , 27,910 controls
]
,
100.0 % Male samples
—European—42 cohorts
  • APCB
  • ,CONOR
  • ,COSM
  • ,CPCS
  • ,CPS
  • ,EPIC
  • ,ERSPC
  • ,FHCRC
  • ,Gene-PARE
  • ,HPFS
  • ,HZ
  • ,IMPACT
  • ,IPO-Porto
  • ,LAAPC
  • ,MCC-Spain
  • ,MCCS
  • ,MDACCS
  • ,MEC
  • ,MOFFITT_PC
  • ,PCMUS
  • ,PCPT
  • ,PHS
  • ,PLCO
  • ,PRAGGA
  • ,PROCAP
  • ,PROFILE
  • ,PROGReSS_PrCa
  • ,Poland
  • ,ProMPT
  • ,ProtecT
  • ,QLD
  • ,RAPPER
  • ,SAAR
  • ,SEARCH
  • ,SFPCS
  • ,SNP_Prostate_Ghent
  • ,SPAG
  • ,STHM
  • ,SWOG-SELECT
  • ,TAMPERE
  • ,TOR
  • ,UKGPCS
These samples (OncoArray) were also used in the GWAS meta-analysis
PSS000068Prostate cancer was classified as localized disease with tumor-node-metastasis stage T2 and below an... d advanced disease (regional-distant) was classified as localized disease with tumor-node-metastasis stage T3 and above (low aggressive tumor, Gleason score <7; intermediate to highly aggressive tumor, Gleason score ≥7). Elevated serum prostate-specific antigen (PSA) levels were defined as ≥4 ng/ml.Show more—
[
  • 2,148 cases
  • , 6,648 controls
]
,
100.0 % Male samples
Range = [50.0, 69.0] yearsEuropean—ProtecT—
PSS000068Prostate cancer was classified as localized disease with tumor-node-metastasis stage T2 and below an... d advanced disease (regional-distant) was classified as localized disease with tumor-node-metastasis stage T3 and above (low aggressive tumor, Gleason score <7; intermediate to highly aggressive tumor, Gleason score ≥7). Elevated serum prostate-specific antigen (PSA) levels were defined as ≥4 ng/ml.Show more—
[
  • 4,099 cases
  • , 960 controls
]
,
100.0 % Male samples
Range = [50.0, 69.0] yearsEuropean—SEARCH—
PSS000068Prostate cancer was classified as localized disease with tumor-node-metastasis stage T2 and below an... d advanced disease (regional-distant) was classified as localized disease with tumor-node-metastasis stage T3 and above (low aggressive tumor, Gleason score <7; intermediate to highly aggressive tumor, Gleason score ≥7). Elevated serum prostate-specific antigen (PSA) levels were defined as ≥4 ng/ml.Show more—
[
  • 3,157 cases
  • , 0 controls
]
,
100.0 % Male samples
Range = [50.0, 60.0] yearsEuropean—UKGPCS—
PSS000069Prostate cancer was classified as localised disease with tumour-node-metastasis (TNM) stage T1-2 N0 ... M0; and advanced disease (regional-distant) with stage T3 and above or any T N1 M1; as non-aggressive tumour, Gleason score <7, and aggressive tumour, Gleason score ⩾7.Show moreMedian = 13.0 years
[
  • 1,089 cases
  • , 3,878 controls
]
,
100.0 % Male samples
Range = [55.0, 71.0] yearsEuropean
(Finnish)		—ERSPC—
PSS000075Breast and prostate cancer cases were defined on the basis of age at diagnosis, whichever occurred f... irst. If breast and prostate cancer occurred at the same time, individuals were treated as patients with breast cancer.Show more—
[
  • 212 cases
  • , 1,313 controls
]
,
100.0 % Male samples
—EuropeanSelf-reported European ancestry37 cohorts
  • BCFR
  • ,BFBOCC
  • ,BRICOH
  • ,CBCS
  • ,CIMBA
  • ,CNIO
  • ,CONSIT
  • ,Chicago
  • ,DEMOKRITOS
  • ,DKFZ
  • ,EMBRACE
  • ,FCCC
  • ,G-FaST
  • ,GC-HBOC
  • ,GEMO
  • ,HCSC
  • ,HEBCS
  • ,HEBON
  • ,HUNBOCS
  • ,HVH
  • ,ICO
  • ,ILUH
  • ,IOVHBOCS
  • ,IPOBCS
  • ,MAYO
  • ,MSKCC
  • ,MUV
  • ,NCI
  • ,OCGN
  • ,OSU
  • ,OUH
  • ,PBCS
  • ,SWE-BRCA
  • ,UPENN
  • ,UPITT
  • ,VFCTG
  • ,kConFab
—
PSS000076——
[
  • 2,012 cases
  • , 1,313 controls
]
,
100.0 % Male samples
—EuropeanSelf-reported European ancestry37 cohorts
  • BCFR
  • ,BFBOCC
  • ,BRICOH
  • ,CBCS
  • ,CIMBA
  • ,CNIO
  • ,CONSIT
  • ,Chicago
  • ,DEMOKRITOS
  • ,DKFZ
  • ,EMBRACE
  • ,FCCC
  • ,G-FaST
  • ,GC-HBOC
  • ,GEMO
  • ,HCSC
  • ,HEBCS
  • ,HEBON
  • ,HUNBOCS
  • ,HVH
  • ,ICO
  • ,ILUH
  • ,IOVHBOCS
  • ,IPOBCS
  • ,MAYO
  • ,MSKCC
  • ,MUV
  • ,NCI
  • ,OCGN
  • ,OSU
  • ,OUH
  • ,PBCS
  • ,SWE-BRCA
  • ,UPENN
  • ,UPITT
  • ,VFCTG
  • ,kConFab
—
PSS000077——
[
  • 53 cases
  • , 1,313 controls
]
,
100.0 % Male samples
—EuropeanSelf-reported European ancestry37 cohorts
  • BCFR
  • ,BFBOCC
  • ,BRICOH
  • ,CBCS
  • ,CIMBA
  • ,CNIO
  • ,CONSIT
  • ,Chicago
  • ,DEMOKRITOS
  • ,DKFZ
  • ,EMBRACE
  • ,FCCC
  • ,G-FaST
  • ,GC-HBOC
  • ,GEMO
  • ,HCSC
  • ,HEBCS
  • ,HEBON
  • ,HUNBOCS
  • ,HVH
  • ,ICO
  • ,ILUH
  • ,IOVHBOCS
  • ,IPOBCS
  • ,MAYO
  • ,MSKCC
  • ,MUV
  • ,NCI
  • ,OCGN
  • ,OSU
  • ,OUH
  • ,PBCS
  • ,SWE-BRCA
  • ,UPENN
  • ,UPITT
  • ,VFCTG
  • ,kConFab
—
PSS000105Men screened with PSA testing, who did not receive a diagnosis of prostate cancer.—4,828 individuals,
100.0 % Male samples
Mean = 59.0 years
IQR = [55.0, 63.0] years		European—ProtecT—
PSS000105Men screened with PSA testing (3.0 ng/L or higher), who received a diagnosis of aggressive prostate ... cancer (defined as any of Gleason score ≥7, stage T3-T4, PSA concentration ≥10 ng/mL, nodal metastasis, or distant metastasis)Show more—
[
  • 628 cases
]
,
100.0 % Male samples
Mean = 64.3 years
IQR = [60.2, 67.5] years		European—ProtecT—
PSS000106Men screened with PSA testing, who did not receive a diagnosis of prostate cancer.—4,828 individuals,
100.0 % Male samples
Mean = 59.0 years
IQR = [55.0, 63.0] years		European—ProtecT—
PSS000106Men screened with PSA testing (3.0 ng/L or higher), who received a diagnosis of prostate cancer.—
[
  • 1,583 cases
]
,
100.0 % Male samples
Mean = 63.4 years
IQR = [59.0, 67.5] years		European—ProtecT—
PSS000107Men screened with PSA testing, who did not receive a diagnosis of prostate cancer.—4,828 individuals,
100.0 % Male samples
Mean = 59.0 years
IQR = [55.0, 63.0] years		European—ProtecT—
PSS000107Men screened with PSA testing (3.0 ng/L or higher), who received a diagnosis of very aggressive pro... state cancer (defined as any of Gleason score ≥8, stage T3-4, positive nodes, or distant metastases)Show more—
[
  • 220 cases
]
,
100.0 % Male samples
—European—ProtecT—
PSS000123Cancer diagnoses were obtained from reigstry data in GERA, and ICD-9/10 codes mapped to ICD-O-3 code... s in UK Biobank. Cancers for this phenotype were classified using the following SEER site recode(s): 28010Show more—
[
  • 10,810 cases
  • , 190,706 controls
]
,
100.0 % Male samples
—European—GERA, UKB—
Showing 1 to 15 of 169 rows
152550100200All
rows per page